Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dupilumab biosimilar - Jiangsu Genscend Biopharmaceutical

Next Previous
Drug Profile

Dupilumab biosimilar - Jiangsu Genscend Biopharmaceutical

Alternative Names: GS-101 - Jiangsu Genscend Biopharmaceutical

Latest Information Update: 23 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Genscend Biopharma
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antifungals; Antineoplastics; Antipruritics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 13 receptor antagonists; Interleukin 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Atopic dermatitis

Most Recent Events

  • 05 Mar 2026 Phase-I clinical trials in Atopic dermatitis (In volunteers) in China (SC) (NCT07411755)
  • 17 Feb 2026 Jiangsu Genscend Biopharma plans a phase I pharmacokinetics, safety, tolerability, and immunogenicity trial for Atopic dermatitis (In volunteers) in China (SC, Injection) in March 2026 (NCT07411755)
  • 04 Feb 2026 Jiangsu Genscend Biopharmaceutical plans a phase III trial for Atopic Dermatitis in China (SC, Injection) in February 2026 (NCT07386743)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top